stockrowSenti Biosciences, Inc.
SNTI Healthcare Biotechnology
Senti Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $22,000.00, down 99.1% from fiscal 2023.
- Revenue
- −98.7%
- EPS
- +26.8%
- Free cash flow
- −7.48%
Quarter to June 2026, against a year earlier
Follow SNTI
Alert me
Senti Biosciences, Inc. (SNTI) EV/Sales
As of 6 November 2026, Senti Biosciences, Inc. (SNTI) trades at a EV/Sales of −1.1×. Over the past ten years it has ranged from −27.8× (September 2022) to 33.0× (October 2022); the current reading is higher than 44% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.7× | — |
| FY2023 | −2.5× | — |
| FY2022 | −13.9× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 21.3× | 238.74% |
| Mar 2026 | 6.3× | — |
| Sep 2023 | −7.7× | — |
| Jun 2023 | −7.8× | — |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CANF Can-Fite Biopharma Ltd compare | −8.7× |
| SNTI Senti Biosciences, Inc. | −1.1× |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| PULM Pulmatrix, Inc. compare | 0.8× |
| CNSY Cerenome, Inc. compare | 1.5× |
| IMNN Imunon, Inc. compare | 6.2× |
| PCSA Heatwurx Inc. compare | 49.5× |
| CDIO Cardio Diagnostics Holdings, Inc. compare | 61.5× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)